Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy

다국어 초록 (Multilingual Abstract)

Although elevated serum low-density lipoprotein-cholesterol (LDL-C) is without any doubts accepted as an important risk factor for cardiovascular disease (CVD), the role of elevated triglycerides (TGs)-rich lipoproteins as an independent risk factor has until recently been quite controversial. Recent data strongly suggest that elevated TG-rich lipoproteins are an independent risk factor for CVD and that therapeutic targeting of them could possibly provide further benefit in reducing CVD morbidity, events and mortality, apart from LDL-C lowering. Today elevated TGs are treated with lifestyle interventions, and with fibrates which could be combined with omega-3 fatty acids. There are also some new drugs. Volanesorsen, is an antisense oligonucleotid that inhibits the production of the Apo C-III which is crucial in regulating TGs metabolism because it inhibits lipoprotein lipase (LPL) and hepatic lipase activity but also hepatic uptake of TGs-rich particles. Evinacumab is a monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3) and it seems that it can substantially lower elevated TGs levels because ANGPTL3 also regulates TGs metabolism. Pemafibrate is a selective peroxisome proliferator-activated receptor alpha modulator which also decreases TGs, and improves other lipid parameters. It seems that it also has some other possible antiatherogenic effects. Alipogene tiparvovec is a nonreplicating adeno-associated viral vector that delivers copies of the LPL gene to muscle tissue which accelerates the clearance of TG-rich lipoproteins thus decreasing extremely high TGs levels. Pradigastat is a novel diacylglycerol acyltransferase 1 inhibitor which substantially reduces extremely high TGs levels and appears to be promising in treatment of the rare familial chylomicronemia syndrome.

참고문헌 (Reference)

• 1 Carbajo MA, "Weight loss and improvement of lipid profiles in morbidly obese patients after laparoscopic one-anastomosis gastric bypass, 2-year follow-up" 31 : 416-421, 2016
• 2 Pecin I, "Volanesorsen(ISIS-APOCIII-LRx)" 41 : 417-421, 2016
• 3 Mosca L, "Usefulness of icosapent ethyl(eicosapentaenoic acid ethyl ester)in women to lower triglyceride levels(results from the MARINE and ANCHOR trials)" 119 : 397-403, 2017
• 4 Sarwar N, "Triglycerides and the risk of coronary heart disease, 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies" 115 : 450-458, 2007
• 5 Miller M, "Triglycerides and cardiovascular disease, a scientific statement from the American Heart Association" 123 : 2292-2333, 2011
• 6 Nordestgaard BG, "Triglycerides and cardiovascular disease" 384 : 626-635, 2014
• 7 Dallinga-Thie GM, "Triglyceride-rich lipoproteins and remnants, targets for therapy?" 18 : 67-, 2016
• 8 Chapman MJ, "Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease, evidence and guidance for management" 32 : 1345-1361, 2011
• 9 Nordestgaard BG, "Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease, new insights from epidemiology, genetics, and biology" 118 : 547-563, 2016
• 10 Vallejo-Vaz AJ, "Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the Treating to New Targets (TNT) trial" Ovid Technologies (Wolters Kluwer Health) 138 (138): 770-781, 2018
• 11 Sarwar N, "Triglyceride-mediated pathways and coronary disease, collaborative analysis of 101 studies" 375 : 1634-1639, 2010
• 12 Reiner Ž, "Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe, findings from the EUROASPIRE III survey" 231 : 300-307, 2013
• 13 Reiner Ž, "Treatment of children with homozygous familial hypercholesterolaemia" 25 : 1095-1097, 2018
• 14 Alaupovic P, "The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial" 17 : 715-722, 1997
• 15 Am J Cardiol, "The residual risk reduction initiative, a call to action to reduce residual vascular risk in patients with dyslipidemia" 102 (102): 1K-34K, 2008
• 16 Fruchart JC, "The residual risk reduction initiative, a call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative(R3I)" 4 : 319-335, 2008
• 17 Hegele RA, "The polygenic nature of hypertriglyceridaemia, implications for definition, diagnosis, and management" 2 : 655-666, 2014
• 18 Black RN, "The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus)a randomised, double-blind controlled trial" 28 : 323-327, 2014
• 19 Hennuyer N, "The novel selective PPARα modulator(SPPARMα)pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis" 249 : 200-208, 2016
• 20 Arca M, "The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome, the results of the ReFOCUS study" 16 : 537-546, 2018
• 21 Davidson M, "The burden of familial chylomicronemia syndrome, results from the global IN-FOCUS study" 12 : 898-907.e2, 2018
• 22 Goulbourne CN, "The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries" 19 : 849-860, 2014
• 23 Ginsberg HN, "The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial, what we learn from subgroup analyses" 34 (34): S107-S108, 2011
• 24 Ray KK, "The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011" 35 : 960-968, 2014
• 25 de Koning L, "Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men" 125 : 1735-1741, 2012
• 26 Chun S, "Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women" 177 : 17-24, 2016
• 27 Reiner Ž, "Statins in the primary prevention of cardiovascular disease" 10 : 453-464, 2013
• 28 Climie RE, "Simple intermittent resistance activity mitigates the detrimental effect of prolonged unbroken sitting on arterial function in overweight and obese adults" 2018
• 29 Tverdal A, "Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men" 129 : 458-465, 1989
• 30 Kim EH, "Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans" 131 : 228-235, 2015
• 31 Fruchart JC, "Selective peroxisome proliferator-activated receptor α modulators(SPPARMα), the next generation of peroxisome proliferator-activated receptor α-agonists" 12 : 82-, 2013
• 32 Bezafibrate Infarction Prevention(BIP)study, "Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease" 102 : 21-27, 2000
• 33 Saeed A, "Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease" 72 : 156-169, 2018
• 34 Joshi PH, "Remnant lipoprotein cholesterol and incident coronary heart disease, the Jackson heart and Framingham offspring cohort studies" 5 : e002765-, 2016
• 35 Varbo A, "Remnant cholesterol as a causal risk factor for ischemic heart disease" 61 : 427-436, 2013
• 36 Kodama S, "Relationship between intake of fruit separately from vegetables and triglycerides-a meta-analysis" 27 : 53-58, 2018
• 37 Robins SJ, "Relation of gemfibrozil treatment and lipid levels with major coronary events, VA-HIT, a randomized controlled trial" 285 : 1585-1591, 2001
• 38 Yang X, "Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy, phase 2 randomized trial results" 57 : 706-713, 2016
• 39 Chadwick AC, "Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3" 137 : 975-977, 2018
• 40 Bhatt DL, "Rationale and design of REDUCE-IT, reduction of cardiovascular events with icosapent ethyl-intervention trial" 40 : 138-148, 2017
• 41 De Backer G, "Prevalence and management of familial hypercholesterolaemia in coronary patients, an analysis of EUROASPIRE IV, a study of the European Society of Cardiology" 241 : 169-175, 2015
• 42 Romeo S, "Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL" 39 : 513-516, 2007
• 43 Faergeman O, "Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease" 104 : 459-463, 2009
• 44 Hokanson JE, "Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level, a meta-analysis of population-based prospective studies" 3 : 213-219, 1996
• 45 Kersten S, "Physiological regulation of lipoprotein lipase" 1841 : 919-933, 2014
• 46 Kieffer SK, "Personal activity intelligence and mortality in patients with cardiovascular disease, the HUNT Study" 93 : 1191-1201, 2018
• 47 Schoonjans K, "PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene" 15 : 5336-5348, 1996
• 48 Fruchart JC, "PPARS, metabolic disease and atherosclerosis" 44 : 345-352, 2001
• 49 Abdelhamid AS, "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease" 7 : CD003177-, 2018
• 50 Kotwal S, "Omega 3 fatty acids and cardiovascular outcomes, systematic review and meta-analysis" 5 : 808-818, 2012
• 51 Nordestgaard BG, "Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women" 298 : 299-308, 2007
• 52 Egeland GM, "Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol, Cohort Norway" 22 : 872-881, 2015
• 53 Puri R, "Non-HDL cholesterol and triglycerides. Implications for coronary atheroma progression and clinical events" 36 : 2220-2228, 2016
• 54 Ginsberg HN, "New perspectives on atherogenesis, role of abnormal triglyceride-rich lipoprotein metabolism" 106 : 2137-2142, 2002
• 55 Jacobson TA, "National Lipid Association recommendations for patient-centered management of dyslipidemia, part 1-executive summary" 8 : 473-488, 2014
• 56 Surendran RP, "Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia" 272 : 185-196, 2012
• 57 Johansen CT, "Mutation skew in genes identified by genome-wide association study of hypertriglyceridemia" 42 : 684-687, 2010
• 58 Caussy C, "Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p. Ser474Ter" 246 : 280-286, 2016
• 59 Ariza MJ, "Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society" 2018
• 60 Holmes MV, "Mendelian randomization of blood lipids for coronary heart disease" 36 : 539-550, 2015
• 61 Reiner Z, "Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients, a clinical update" 23 : 799-807, 2013
• 62 Reiner Ž, "Management of patients with familial hypercholesterolaemia" 12 : 565-575, 2015
• 63 Di Angelantonio E, "Major lipids, apolipoproteins, and risk of vascular disease" 302 : 1993-2000, 2009
• 64 Patel L, "Low-calorie beverage consumption, diet quality and cardiometabolic risk factors in British adults" 10 : E1261-, 2018
• 65 Thomsen M, "Low nonfasting triglycerides and reduced all-cause mortality, a mendelian randomization study" 60 : 737-746, 2014
• 66 Crosby J, "Loss-of-function mutations in APOC3, triglycerides, and coronary disease" 371 : 22-31, 2014
• 67 Gaudet D, "Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis" 27 : 916-925, 2016
• 68 Cohen DE, "Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease" 33 : 380-388, 2013
• 69 Wang H, "Lipoprotein lipase, from gene to obesity" 297 : E271-E288, 2009
• 70 Goldberg IJ, "Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV" 265 : 4266-4272, 1990
• 71 American City Business Journals, "Landmark trial entitled "PROMINENT" to explore the prevention of heart disease in diabetic patients with high triglycerides and low HDL-C [Internet]"
• 72 Hussain MM, "Intestinal lipid absorption and lipoprotein formation" 25 : 200-206, 2014
• 73 Baldi S, "Influence of apolipoproteins on the association between lipids and insulin sensitivity, a cross-sectional analysis of the RISC Study" 36 : 4125-4131, 2013
• 74 Nichols GA, "Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterol" 2018
• 75 Makoveichuk E, "Inactivation of LPL occurs on the surface of THP-1 macrophages where oligomers of ANGPTL4 are formed" 425 : 138-143, 2012
• 76 Dewey FE, "Inactivating variants in ANGPTL4 and risk of coronary artery disease" 374 : 1123-1133, 2016
• 77 Vanhees L, "Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors, recommendations from the EACPR. Part II" 19 : 1005-1033, 2012
• 78 Miller M, "Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial" 51 : 724-730, 2008
• 79 Reiner Z, "Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia" 114 : 233-235, 2014
• 80 Liu J, "Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level, a 15-year follow-up of the Chinese Multi-provincial Cohort Study" 96 : 217-224, 2012
• 81 Moulin P, "Identification and diagnosis of patients with familial chylomicronaemia syndrome(FCS), expert panel recommendations and proposal of an"FCS score"" 275 : 265-272, 2018
• 82 Nelson SD, "Icosapent ethyl for treatment of elevated triglyceride levels" 47 : 1517-1523, 2013
• 83 Kastelein JJ, "Icosabutate, a structurally engineered fatty acid, improves the cardiovascular risk profile in statin-treated patients with residual hypertriglyceridemia" 135 : 3-12, 2016
• 84 Goldstein JL, "Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia" 52 : 1544-1568, 1973
• 85 Frick MH, "Helsinki Heart Study, primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease" 317 : 1237-1245, 1987
• 86 Beigneux AP, "Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons" 5 : 279-291, 2007
• 87 Austin MA, "Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia" 44 : 2161-2168, 2003
• 88 Kurano M, "Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglyceride" 61 : 427-433, 2016
• 89 Jørgensen AB, "Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction" 34 : 1826-1833, 2013
• 90 Dewey FE, "Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease" 377 : 211-221, 2017
• 91 Millan J, "Fibrates in the secondary prevention of cardiovascular disease(infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration" 30 : 30-35, 2018
• 92 Harmer JA, "Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus, a FIELD substudy" 141 : 156-167, 2018
• 93 Schwartz GG, "Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins" 65 : 2267-2275, 2015
• 94 Iso H, "Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women, the Circulatory Risk in Communities Study(CIRCS)" 237 : 361-368, 2014
• 95 Schlein C, "FGF21 lowers plasma triglycerides by accelerating lipoprotein c atabolism in white and brown adipose tissues" 23 : 441-453, 2016
• 96 Hansen D, "Exercise prescription in patients with different combinations of cardiovascular disease risk factors, a consensus statement from the EXPERT working group" 48 : 1781-1797, 2018
• 97 Perk J, "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)" 33 : 1635-1701, 2012
• 98 Hulley SB, "Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease" 302 : 1383-1389, 1980
• 99 MDText.com, "Endotext [Internet]"
• 100 Stanhope KL, "Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup" 88 : 1733S-1737S, 2008
• 101 Klempfner R, "Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease, twenty-two-year follow-up of the bezafibrate infarction prevention study and registry" 9 : 100-108, 2016
• 102 Arai H, "Efficacy and Safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels, a multicenter, placebo-controlled, double-blind, randomized trial" 25 : 521-538, 2018
• 103 Dattilo AM, "Effects of weight reduction on blood lipids and lipoproteins, a meta-analysis" 56 : 320-328, 1992
• 104 Bajaj M, "Effects of peroxisome proliferator-activated receptor(PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus" 50 : 1723-1731, 2007
• 105 Yamashita S, "Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia" 12 : 1267-1279.e4., 2018
• 106 ASCEND Study Collaborative Group, "Effects of n-3 fatty acid supplements in diabetes mellitus" 2018
• 107 Nordmann AJ, "Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors, a meta-analysis of randomized controlled trials" 166 : 285-293, 2006
• 108 Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study), randomised controlled trial" 366 : 1849-1861, 2005
• 109 Jun M, "Effects of fibrates on cardiovascular outcomes, a systematic review and meta-analysis" 375 : 1875-1884, 2010
• 110 Ginsberg HN, "Effects of combination lipid therapy in type 2 diabetes mellitus" 362 : 1563-1574, 2010
• 111 Matsuba I, "Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance" 2018
• 112 Ishibashi S, "Effects of K-877, a novel selective PPARα modulator(SPPARMα), in dyslipidaemic patients, a randomized, double blind, active-and placebo-controlled, phase 2 trial" 249 : 36-43, 2016
• 113 Meyers CD, "Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome" 14 : 8-, 2015
• 114 Sahebkar A, "Effect of statin therapy on plasma apolipoprotein C-III concentrations, a systematic review and meta-analysis of randomized controlled trials" 12 : 801-809, 2018
• 115 Sahebkar A, "Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations, a systematic review and meta-analysis of randomized controlled trials" 1 (1): 2018
• 116 Grønholdt ML, "Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins" 27 : 2166-2172, 1996
• 117 Liu ZM, "Early investigational drugs targeting PPAR-α for the treatment of metabolic disease" 24 : 611-621, 2015
• 118 Reiner Z, "ESC/EAS Guidelines for the management of dyslipidaemias, the Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS)" 32 : 1769-1818, 2011
• 119 Graham I, "Dyslipidemias in the prevention of cardiovascular disease, risks and causality" 14 : 709-720, 2012
• 120 Mehta N, "Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits" 34 : 1057-1063, 2014
• 121 Veerkamp MJ, "Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families, results of a 5-year follow-up study" 22 : 274-282, 2002
• 122 Ferrari R, "Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia" 18 (18): C2-C12, 2016
• 123 Carey VJ, "Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control" 106 : 757-763, 2010
• 124 Stanhope KL, "Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans" 119 : 1322-1334, 2009
• 125 Do R, "Common variants associated with plasma triglycerides and risk for coronary artery disease" 45 : 1345-1352, 2013
• 126 Reiner Z, "Combined therapy in the treatment of dyslipidemia" 24 : 19-28, 2010
• 127 Stitziel NO, "Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease" 374 : 1134-1144, 2016
• 128 Graham MJ, "Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides" 377 : 222-232, 2017
• 129 Lind L, "Can the plasma concentration ratio of triglyceride/high-density lipoprotein cholesterol identify individuals at high risk of cardiovascular disease during 40-year follow-up?" 16 : 433-439, 2018
• 130 Shiochi H, "Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus, a small-scale clinical study" 6 : 113-, 2014
• 131 Sacks FM, "Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus, a global case-control study in 13 countries" 129 : 999-1008, 2014
• 132 Nicholls SJ, "Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol, rationale and design of the STRENGTH trial" 2018
• 133 Li Y, "Apolipoprotein C3 gene variants and the risk of coronary heart disease, a meta-analysis" 9 : 104-109, 2016
• 134 Huff MW, "Apolipoprotein C-III, going back to the future for a lipid drug target" 112 : 1405-1408, 2013
• 135 Norata GD, "Apolipoprotein C-III, from pathophysiology to pharmacology" 36 : 675-687, 2015
• 136 Graham MJ, "Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans" 112 : 1479-1490, 2013
• 137 Gaudet D, "Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia" 373 : 438-447, 2015
• 138 Johansen CT, "An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia" 31 : 1916-1926, 2011
• 139 Goff DC Jr, "American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2013 ACC/AHA guideline on the assessment of cardiovascular risk, a report of the American College of Cardiology/American Heart Association Task Force on Practice" 129 (129): 49-73, 2014
• 140 Šimić I, "Adverse effects of statins-myths and reality" 21 : 1220-1226, 2015
• 141 Vatner DF, "ANGPTL8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents" 61 : 1435-1446, 2018
• 142 Gaudet D, "ANGPTL3 inhibition in homozygous familial hypercholesterolemia" 377 : 296-297, 2017
• 143 Sahebkar A, "A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma homocysteine levels" 23 : 4490-4503, 2016
• 144 Aguiar C, "A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia, A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy" 19 : 1-12, 2015
• 145 Karlson BW, "A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia" 117 : 1444-1448, 2016
• 146 Catapano AL, "2016 ESC/EAS guidelines for the management of dyslipidaemias" 37 : 2999-3058, 2016